Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1923]

Comment: Adjuvant ipilimumab in high-risk melanoma

Dr Steven O'Day - Beverly Hills Cancer Center, Los Angeles, USA

Comment: Adjuvant ipilimumab in high-risk melanoma ( Dr Steven O'Day - Beverly Hills Cancer Center, Los Angeles, USA )

Comment: PD-1 targeting MK-3475 gives long-term responses in melanoma

Dr Steven O'Day - Beverly Hills Cancer Center, Los Angeles, USA

Comment: PD-1 targeting MK-3475 gives long-term responses in melanoma ( Dr Steven O'Day - Beverly Hills Cancer Center, Los Angeles, USA )

Comment: Immunotherapy combo increases median survival in advanced melanoma

Dr Steven O'Day - Beverly Hills Cancer Center, Los Angeles, USA

Comment: Immunotherapy combo increases median survival in advanced melanoma ( Dr Steven O'Day - Beverly Hills Cancer Center, Los Angeles, USA )

Success for ipilimumab and nivolumab combo in advanced melanoma

Prof Mario Sznol - Yale Cancer Center, New Haven, USA

Success for ipilimumab and nivolumab combo in advanced melanoma ( Prof Mario Sznol - Yale Cancer Center, New Haven, USA )

Comment: CALGB/SWOG 80405 study on chemo combos in colorectal

Prof Marc Peeters - University of Antwerp, Antwerp, Belgium

Comment: CALGB/SWOG 80405 study on chemo combos in colorectal ( Prof Marc Peeters - University of Antwerp, Antwerp, Belgium )

Blinatumomab shown to be beneficial in relapsed/refractory B-precursor acute...

Prof Max Topp - Würzburg University Hospital, Würzburg, Germany

$Blinatumomab shown to be beneficial in relapsed/refractory B-precursor acute lymphoblastic leukaemia ( Prof Max Topp - Würzburg University Hospital, Würzburg, Germany )$

ASCO 2014 roundup

Prof Gordon McVie - ecancer and European Institute of Oncology, Milan, Italy

ASCO 2014 roundup ( Prof Gordon McVie - ecancer and European Institute of Oncology, Milan, Italy )

T-VEC injections into melanoma lesions show significant response rate

Prof Kevin Harrington - Institute of Cancer Research, London, UK

T-VEC injections into melanoma lesions show significant response rate ( Prof Kevin Harrington - Institute of Cancer Research, London, UK )

ASCO 2014: Advances in prostate cancer discussion

Prof Noel Clarke; Dr Cora Sternberg; Dr Kurt Miller, Prof Wysocki

ASCO 2014: Advances in prostate cancer discussion ( Prof Noel Clarke; Dr Cora Sternberg; Dr Kurt Miller, Prof Wysocki )

Adjuvant exemestane is more effective than tamoxifen when combined with ovarian...

Dr Olivia Pagani - Oncology Institute of Southern Switzerland, Bellinzona...

Adjuvant exemestane is more effective than tamoxifen when combined with ovarian function suppression in young women with hormone-sensitive, early-stage breast cancer ( Dr Olivia Pagani - Oncology Institute of Southern Switzerland, Bellinzona, Switzerland )

Comment: Advances in breast cancer presented at ASCO 2014

Prof Jacek Jassem - Gdańsk Medical University, Gdańsk, Poland

Comment: Advances in breast cancer presented at ASCO 2014 ( Prof Jacek Jassem - Gdańsk Medical University, Gdańsk, Poland )

Medyczne nowości w raku gruczołu krokowego

Prof Piotr Jan Wysocki - Poznan University of Medical Sciences, Poznan, Poland

Medyczne nowości w raku gruczołu krokowego ( Prof Piotr Jan Wysocki - Poznan University of Medical Sciences, Poznan, Poland )

More from ecancer